Migraine preventive treatment benefits may go beyond fewer headache days. A new study links erenumab to improved symptoms of anxiety, depression, and poor sleep quality in some people with migraine. Molly O'Brien has the details in this Migraine Minute News Update.

Read More: https://bit.ly/3LJl3r7

Script: A new study suggests that one migraine treatment may offer benefits beyond less headache days. Researchers found that the CGRP monoclonal antibody erenumab, sold under the brand name Aimovig, not only reduces migraine frequency… but may improve symptoms of anxiety, depression, and poor sleep quality in some adults with migraine.

Participants took 140MG of erenumab monthly. Over the course of the 24 weeks those who had at least a 50 percent drop in monthly migraine days ALSO saw improved anxiety, depression, and sleep quality. The authors say improvements are likely driven by better migraine control rather than a direct effect of the medication. Researchers also say this study highlights how good migraine prevention may improve overall well-being and quality of life.